JP2012520896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520896A5 JP2012520896A5 JP2012500955A JP2012500955A JP2012520896A5 JP 2012520896 A5 JP2012520896 A5 JP 2012520896A5 JP 2012500955 A JP2012500955 A JP 2012500955A JP 2012500955 A JP2012500955 A JP 2012500955A JP 2012520896 A5 JP2012520896 A5 JP 2012520896A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- treatment
- trifluoropentanamide
- deutero
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- FYLZPFSWVMMCQC-UHFFFAOYSA-N 5,5,5-trifluoropentanamide Chemical compound NC(=O)CCCC(F)(F)F FYLZPFSWVMMCQC-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16162909P | 2009-03-19 | 2009-03-19 | |
| US61/161,629 | 2009-03-19 | ||
| PCT/US2010/027780 WO2010107984A1 (en) | 2009-03-19 | 2010-03-18 | Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production a novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520896A JP2012520896A (ja) | 2012-09-10 |
| JP2012520896A5 true JP2012520896A5 (enExample) | 2013-04-11 |
Family
ID=42312995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500955A Ceased JP2012520896A (ja) | 2009-03-19 | 2010-03-18 | ベータアミロイドペプチド産生阻害剤としての重水素化された新規アルファ−（ｎ−スルホンアミド）アセトアミド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8044077B2 (enExample) |
| EP (1) | EP2408757B1 (enExample) |
| JP (1) | JP2012520896A (enExample) |
| CN (1) | CN102356071A (enExample) |
| AR (1) | AR075903A1 (enExample) |
| TW (1) | TW201038266A (enExample) |
| WO (1) | WO2010107984A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2325205T3 (es) | 2001-12-20 | 2009-08-28 | Bristol-Myers Squibb Company | Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides. |
| US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE225779T1 (de) | 1995-11-17 | 2002-10-15 | Warner Lambert Co | Sulfonamidinhibitoren von matrix metalloproteinasen |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| CN1224612C (zh) | 1999-01-27 | 2005-10-26 | 惠氏控股有限公司 | 炔基磺酰胺硫醇tace抑制剂 |
| MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| ES2325205T3 (es) | 2001-12-20 | 2009-08-28 | Bristol-Myers Squibb Company | Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides. |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| UA82093C2 (uk) | 2003-03-31 | 2008-03-11 | Уайт | Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні |
| CA2544350A1 (en) | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| AU2005261932B2 (en) | 2004-07-13 | 2011-10-13 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| AR059518A1 (es) | 2006-02-17 | 2008-04-09 | Wyeth Corp | Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| EP1984347A1 (en) | 2006-02-17 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| WO2009137657A1 (en) | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | 2-aryl glycinamide derivatives |
| SG173797A1 (en) | 2009-03-19 | 2011-09-29 | Bristol Myers Squibb Co | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-03-15 US US12/723,936 patent/US8044077B2/en active Active
- 2010-03-18 CN CN2010800122954A patent/CN102356071A/zh active Pending
- 2010-03-18 WO PCT/US2010/027780 patent/WO2010107984A1/en not_active Ceased
- 2010-03-18 JP JP2012500955A patent/JP2012520896A/ja not_active Ceased
- 2010-03-18 EP EP10723826.3A patent/EP2408757B1/en not_active Not-in-force
- 2010-03-19 AR ARP100100898A patent/AR075903A1/es not_active Application Discontinuation
- 2010-03-19 TW TW099108209A patent/TW201038266A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110219T1 (hr) | Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida | |
| JP2019059760A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| MX2011011489A (es) | Derivados de isoxazol-piridina. | |
| JP2018168191A5 (enExample) | ||
| MX381504B (es) | Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina. | |
| MX2011011477A (es) | Derivados de isoxazol-piridazina. | |
| WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
| JP2014511893A5 (enExample) | ||
| IL189546A0 (en) | Therapy for the treatment of disease | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| JP2007514005A5 (enExample) | ||
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| JP2012512158A5 (enExample) | ||
| BRPI0517227A (pt) | forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição | |
| IL190652A0 (en) | Novel pharmaceutical combinations for the treatment of respiratory disorders | |
| JP2012524092A5 (enExample) | ||
| EP1615664A4 (en) | PHARMACEUTICAL COMPOSITION USEFUL IN THE TREATMENT OF IMMUNOLOGICAL DISORDERS | |
| JP2015500223A5 (enExample) | ||
| WO2007135026A3 (de) | Substituierte pteridine als therapeutika | |
| JP2021522291A5 (enExample) | ||
| NZ595335A (en) | Pharmaceutical comprising (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide with enhanced bioavailability and solubility | |
| TWI372056B (en) | Novel medicament combinations for the treatment of respiratory diseases |